|Articles|November 1, 2022
Supplements and Featured Publications
- Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update
- Volume 28
- Issue 12
Biosimilar medicines: what are they and how are they used?
Plain Language Summary
Advertisement
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5

